434 related articles for article (PubMed ID: 22552325)
1. Endothelin-1 cooperates with hypoxia to induce vascular-like structures through vascular endothelial growth factor-C, -D and -A in lymphatic endothelial cells.
Garrafa E; Caprara V; Di Castro V; Rosanò L; Bagnato A; Spinella F
Life Sci; 2012 Oct; 91(13-14):638-43. PubMed ID: 22552325
[TBL] [Abstract][Full Text] [Related]
2. Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade.
Spinella F; Garrafa E; Di Castro V; Rosanò L; Nicotra MR; Caruso A; Natali PG; Bagnato A
Cancer Res; 2009 Mar; 69(6):2669-76. PubMed ID: 19276384
[TBL] [Abstract][Full Text] [Related]
3. Endothelin axis induces metalloproteinase activation and invasiveness in human lymphatic endothelial cells.
Spinella F; Caprara V; Garrafa E; Di Castro V; Rosanò L; Natali PG; Bagnato A
Can J Physiol Pharmacol; 2010 Aug; 88(8):782-7. PubMed ID: 20725135
[TBL] [Abstract][Full Text] [Related]
4. Suppression of lymphangiogenesis in human lymphatic endothelial cells by simultaneously blocking VEGF-C and VEGF-D/VEGFR-3 with norcantharidin.
Liu ZY; Qiu HO; Yuan XJ; Ni YY; Sun JJ; Jing W; Fan YZ
Int J Oncol; 2012 Nov; 41(5):1762-72. PubMed ID: 22922710
[TBL] [Abstract][Full Text] [Related]
5. Molecular control of lymphatic metastasis.
Achen MG; Stacker SA
Ann N Y Acad Sci; 2008; 1131():225-34. PubMed ID: 18519975
[TBL] [Abstract][Full Text] [Related]
6. Expression of VEGF-C and VEGF-D as significant markers for assessment of lymphangiogenesis and lymph node metastasis in non-small cell lung cancer.
Feng Y; Wang W; Hu J; Ma J; Zhang Y; Zhang J
Anat Rec (Hoboken); 2010 May; 293(5):802-12. PubMed ID: 20225197
[TBL] [Abstract][Full Text] [Related]
7. Endothelin-1 induces the transactivation of vascular endothelial growth factor receptor-3 and modulates cell migration and vasculogenic mimicry in melanoma cells.
Spinella F; Caprara V; Di Castro V; Rosanò L; Cianfrocca R; Natali PG; Bagnato A
J Mol Med (Berl); 2013 Mar; 91(3):395-405. PubMed ID: 22965194
[TBL] [Abstract][Full Text] [Related]
8. Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
Davydova N; Harris NC; Roufail S; Paquet-Fifield S; Ishaq M; Streltsov VA; Williams SP; Karnezis T; Stacker SA; Achen MG
J Biol Chem; 2016 Dec; 291(53):27265-27278. PubMed ID: 27852824
[TBL] [Abstract][Full Text] [Related]
9. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
[TBL] [Abstract][Full Text] [Related]
10. Lymphangiogenesis and its relationship with lymphatic metastasis and prognosis in malignant melanoma.
Liu B; Ma J; Wang X; Su F; Li X; Yang S; Ma W; Zhang Y
Anat Rec (Hoboken); 2008 Oct; 291(10):1227-35. PubMed ID: 18561194
[TBL] [Abstract][Full Text] [Related]
11. Lymphangiogenesis in aortic valve stenosis--novel regulatory roles for valvular myofibroblasts and mast cells.
Syväranta S; Helske S; Lappalainen J; Kupari M; Kovanen PT
Atherosclerosis; 2012 Apr; 221(2):366-74. PubMed ID: 22281299
[TBL] [Abstract][Full Text] [Related]
12. DNA demethylation of vascular endothelial growth factor-C is associated with gene expression and its possible involvement of lymphangiogenesis in gastric cancer.
Matsumura S; Oue N; Mitani Y; Kitadai Y; Yasui W
Int J Cancer; 2007 Apr; 120(8):1689-95. PubMed ID: 17230534
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 matrix protein p17 promotes lymphangiogenesis and activates the endothelin-1/endothelin B receptor axis.
Caccuri F; Rueckert C; Giagulli C; Schulze K; Basta D; Zicari S; Marsico S; Cervi E; Fiorentini S; Slevin M; Guzman CA; Caruso A
Arterioscler Thromb Vasc Biol; 2014 Apr; 34(4):846-56. PubMed ID: 24482377
[TBL] [Abstract][Full Text] [Related]
14. The interplay between hypoxia, endothelial and melanoma cells regulates vascularization and cell motility through endothelin-1 and vascular endothelial growth factor.
Spinella F; Caprara V; Cianfrocca R; Rosanò L; Di Castro V; Garrafa E; Natali PG; Bagnato A
Carcinogenesis; 2014 Apr; 35(4):840-8. PubMed ID: 24473118
[TBL] [Abstract][Full Text] [Related]
15. Vascular Endothelial Growth Factor and Podocyte Protection in Chronic Hypoxia: Effects of Endothelin-A Receptor Antagonism.
Harvey TW; Engel JE; Chade AR
Am J Nephrol; 2016; 43(2):74-84. PubMed ID: 26930122
[TBL] [Abstract][Full Text] [Related]
16. Semaphorin 4D expression is associated with a poor clinical outcome in cervical cancer patients.
Liu H; Yang Y; Xiao J; Yang S; Liu Y; Kang W; Li X; Zhang F
Microvasc Res; 2014 May; 93():1-8. PubMed ID: 24603190
[TBL] [Abstract][Full Text] [Related]
17. Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer.
Yang H; Kim C; Kim MJ; Schwendener RA; Alitalo K; Heston W; Kim I; Kim WJ; Koh GY
Mol Cancer; 2011 Apr; 10():36. PubMed ID: 21481239
[TBL] [Abstract][Full Text] [Related]
18. Endothelin-1 regulates hypoxia-inducible factor-1α and -2α stability through prolyl hydroxylase domain 2 inhibition in human lymphatic endothelial cells.
Caprara V; Scappa S; Garrafa E; Di Castro V; Rosanò L; Bagnato A; Spinella F
Life Sci; 2014 Nov; 118(2):185-90. PubMed ID: 24607784
[TBL] [Abstract][Full Text] [Related]
19. Lymphangiogenesis and angiogenesis in bladder cancer: prognostic implications and regulation by vascular endothelial growth factors-A, -C, and -D.
Miyata Y; Kanda S; Ohba K; Nomata K; Hayashida Y; Eguchi J; Hayashi T; Kanetake H
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):800-6. PubMed ID: 16467091
[TBL] [Abstract][Full Text] [Related]
20. The β
Kumaravel S; Abbey CA; Bayless KJ; Chakraborty S
Am J Physiol Cell Physiol; 2020 Dec; 319(6):C1045-C1058. PubMed ID: 33052069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
